Literature DB >> 11882066

Zolpidem in progressive supranuclear palsy.

Brigitte J Mayr, Raphael M Bonelli, Gerald Niederwieser, Peter Költringer, Franz Reisecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11882066     DOI： 10.1046/j.1468-1331.2002.0354g.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  5 in total

1.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem.

Authors:  Romy Hoque; Andrew L Chesson
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

3.  Trial of Zolpidem, Eszopiclone, and Other GABA Agonists in a Patient with Progressive Supranuclear Palsy.

Authors:  Andrew Young Chang; Erica Weirich
Journal:  Case Rep Med       Date:  2014-09-16

4.  Zolpidem in progressive supranuclear palsy.

Authors:  Sandip K Dash
Journal:  Case Rep Neurol Med       Date:  2013-05-09

Review 5.  Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.

Authors:  Antonio Daniele; Francesco Panza; Antonio Greco; Giancarlo Logroscino; Davide Seripa
Journal:  Parkinsons Dis       Date:  2016-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.